Enith2NCT07351058
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 11 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 210 → 222 locations
- Notable Eligibility criteria expanded, about 14 words
- Trial sites expanded: 204 → 210 locations
- Secondary endpoints: details revised at 4 of 40 entries
- Minor Trial sites expanded: 193 → 204 locationsv10
- Minor Trial sites expanded: 163 → 193 locationsv9
- Minor Trial sites expanded: 122 → 163 locationsv8
- Minor Trial sites expanded: 61 → 122 locationsv7
- Minor Trial sites expanded: 36 → 61 locationsv6
- Minor Trial sites expanded: 28 → 36 locations
- Interventions: Placebo (Combination Product), RO7795068 (Combination Product) to Enicepatide (Combination Product), Placebo (Combination Product)
- Study title expanded, about 1 word
- Minor Trial sites expanded: 3 → 28 locations
- Start date changed from estimate of Mar 31, 2026 to Mar 23, 2026
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Feb 27, 2026 to Mar 31, 2026
- Study sites: 0 to 3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percent (%) Change from Baseline in Body Weight at Week 72
Timeframe: Baseline through Week 72
Secondary (40)
Percentage of Participants Achieving ≥5% Body Weight Loss from Baseline at Week 72
Percentage of Participants Achieving ≥10% Body Weight Loss from Baseline at Week 72
Percentage of Participants Achieving ≥15% Body Weight Loss from Baseline at Week 72
Change from Baseline in Body Weight (kg) at Week 72
Change from Baseline in Hemoglobin A1c (HbA1c) at Week 72
Show 35 moreShow less
Percentage of Participants Achieving HbA1c of ≤6.5% at Week 72
Percentage of Participants Achieving HbA1c of <7% at Week 72
Change from Baseline in Waist Circumference (cm) at Week 72
Change from Baseline in Fasting Glucose at Week 72
Change from Baseline in Fasting Insulin at Week 72
Change from Baseline in Low-Density Lipoprotein (LDL) Cholesterol at Week 72
Change from Baseline in High-Density Lipoprotein (HDL) Cholesterol at Week 72
Change from Baseline in Triglyceride at Week 72
Change from Baseline in Systolic Blood Pressure at Week 72
Change from Baseline in the Physical Functioning Domain Score of the Short Form (36) Health Survey Version 2 (SF-36v2) Acute Form at Week 72
Change from Baseline in Physical Functioning Composite Score of the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQoL-Lite-CT) Questionnaire at Week 72
Change from Baseline in Waist-to-Hip Ratio at Week 72
Change from Baseline in Waist-to-Height Ratio at Week 72
Change from Baseline in Subscale Scores of the Control of Eating Questionnaire (CoEQ) at Week 72
Change from Baseline in Symptoms and Impact of Urinary Incontinence as Assessed by the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) at Week 72
Percentage of Participants Experiencing No Change, Improvement, or Worsening on the Patient Global Impression of Change (PGI-C) Urinary Incontinence Questionnaire at Week 72
Percentage of Participants Experiencing No Change, Improvement, or Worsening on the Patient Global Impression of Severity (PGI-S) Urinary Incontinence Questionnaire at Week 72
Percentage of Participants Experiencing No Change, Improvement, or Worsening on the PGI-C Physical Functioning Questionnaire at Week 72
Percentage of Participants Experiencing No Change, Improvement, or Worsening on the PGI-S Physical Functioning Questionnaire at Week 72
Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the SF-36v2 Acute Form Domain Scores and Component Summary Scores at Week 72
Change from Baseline in HRQoL as Assessed by the IWQoL-Lite-CT Domain Scores and Total Score at Week 72
Change from Baseline in Non-HDL Cholesterol at Week 72
Change from Baseline in VLDL Cholesterol at Week 72
Change from Baseline in Total Cholesterol at Week 72
Change from Baseline in Free Fatty Acids at Week 72
Change from Baseline in Diastolic Blood Pressure at Week 72
Change from Baseline in High-Sensitivity C-reactive Protein (hsCRP) at Week 72
Change from Baseline in Urinary Albumin/Creatinine Ratio at Week 72
Change from Baseline in Body Mass Index (BMI) at Week 72
Percent (%) Change from Baseline in Body Weight by Obesity Class at Week 72
Time to Achieve ≥5%, ≥10%, or ≥15% Body Weight Loss from Baseline Through Week 72
Percentage of Participants Achieving HbA1c of <5.7% at Week 72
Incidence and Severity of Adverse Events, with Severity Determined According to Mild/Moderate/Severe Criteria
Change from Baseline in the Columbia-Suicide Severity Rating Scale (C-SSRS) Score Through Week 72
Change from Baseline in the Patient Health Questionnaire-9 (PHQ-9) Score Through Week 72
Arms and interventions
Arm 1: PlaceboPlacebo comparator
Arm 2: Enicepatide Dosing Regimen 1Experimental
Arm 3: Enicepatide Dosing Regimen 2Experimental
Arm 4: Enicepatide Dosing Regimen 3Experimental
Combination products: Placebo, Enicepatide
Sites
222 sites in 22 countries
United States 45, China 25, Germany 12, Poland 10, South Korea 10, Spain 10, United Kingdom 10, Mexico 9, Brazil 8, Canada 8, India 8, Italy 8, Taiwan 8, Turkey (Türkiye) 8, Argentina 7, Japan 7, Australia 6, Czechia 6, Thailand 6, France 5, Romania 5, Puerto Rico 1